TREVI THERAPEUTICS PROVIDES STRATEGIC UPDATES AHEAD OF ANNUAL LIFESCI PARTNERS CORPORATE ACCESS EVENT HELD DURING THE J.P. MORGAN HEALTHCARE CONFERENCE
TREVI THERAPEUTICS INC - FDA END-OF-PHASE 2 MEETING SCHEDULED FOR Q1 2026
TREVI THERAPEUTICS INC - PHASE 2B REFRACTORY CHRONIC COUGH TRIAL TO START IN H1 2026
Source text: ID:nPn6wmY2Pa
Further company coverage: TRVI.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.